Twist Bioscience Corporation Common Stock Earnings Dividend

Twist Bioscience Corporation Common Stock’s revenue jumped 19.31% since last year same period to $110.72Mn in the Q1 2026. On a quarterly growth basis, Twist Bioscience Corporation Common Stock has generated 6.77% jump in its revenue since last 3-months.

Twist Bioscience Corporation Common Stock’s net profit fell -11.93% since last year same period to $-44.02Mn in the Q1 2026. On a quarterly growth basis, Twist Bioscience Corporation Common Stock has generated -44.3% fall in its net profits since last 3-months.

Twist Bioscience Corporation Common Stock’s net profit margin jumped 6.19% since last year same period to -39.76% in the Q1 2026. On a quarterly growth basis, Twist Bioscience Corporation Common Stock has generated -35.15% fall in its net profit margins since last 3-months.

Twist Bioscience Corporation Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.49 - a -2.08% fall from last quarter’s estimates.

Twist Bioscience Corporation Common Stock’s earning per share (EPS) estimates for the current year stand at -0.49.

Twist Bioscience Corporation Common Stock’s earning per share (EPS) fell -7.58% since last year same period to -0.71 in the Q1 2026. This indicates that the Twist Bioscience Corporation Common Stock has generated -7.58% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Twist Bioscience Corporation Common Stock’s return on assets (ROA) stands at -0.13.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Twist Bioscience Corporation Common Stock’s return on equity (ROE) stands at -0.18.